Long COVID Treatment: What Peptide Research Shows

Long COVID (post-COVID-19 syndrome) refers to symptoms persisting beyond 12 weeks after initial SARS-CoV-2 infection. The ONS estimates approximately 2 million people in the UK have experienced long COVID, with around 800,000 reporting that it limits their daily activities.

Common symptoms: - Fatigue: The most reported symptom (>60% of cases), often debilitating and not relieved by rest - Brain fog: Cognitive difficulties including memory problems, concentration issues, and word-finding difficulties - Breathlessness: Often disproportionate to lung function test results - Pain: Muscle pain, joint pain, headaches, chest pain - Cardiovascular: Palpitations, tachycardia, exercise intolerance - Autonomic dysfunction: Postural tachycardia (PoTS-like symptoms)

Proposed mechanisms: - Persistent viral reservoirs or viral fragments - Autoimmune activation (molecular mimicry) - Endothelial dysfunction and microclotting - Mitochondrial dysfunction - Chronic neuroinflammation

These proposed mechanisms overlap with pathways targeted by several research peptides, which is why the peptide community has shown interest in this area.

Thymosin Alpha-1 (most relevant) An immune-modulating peptide that enhances T-cell function and reduces inflammatory cytokines: - Used during acute COVID-19 in some countries (particularly China and Italy) to support immune response - Approved in 35+ countries for hepatitis B and immune deficiency (NOT approved in UK) - Theoretical relevance to long COVID: may help normalise dysregulated immune responses - Limited specific long COVID data — extrapolated from acute COVID and general immune research

BPC-157 A cytoprotective peptide researched for anti-inflammatory and tissue repair properties: - Animal studies show effects on multiple inflammatory pathways - Theoretical relevance: may address the inflammatory component of long COVID - No human data for COVID or long COVID applications - Some researchers hypothesise gut-healing properties could address GI manifestations of long COVID

MOTS-c A mitochondrial-derived peptide that regulates cellular energy metabolism: - Improves mitochondrial function and insulin sensitivity in research - Theoretical relevance: mitochondrial dysfunction is proposed as a key long COVID mechanism - May address the exercise intolerance and fatigue components - Very limited human data overall

SS-31 (Elamipretide) Targets the inner mitochondrial membrane: - Clinical trials exist for mitochondrial myopathies and heart failure - Theoretical relevance: stabilises mitochondrial function, which may be impaired in long COVID - More advanced clinical development than MOTS-c but not for COVID indications

Selank A neuropeptide with anxiolytic and nootropic properties: - May address the brain fog and cognitive components of long COVID - Approved in Russia for anxiety and cognitive enhancement - Intranasal administration allows potential CNS access - No specific long COVID research

Critical context: No peptide has been proven effective for long COVID treatment in rigorous clinical trials.

The current state of evidence:

What we have: - Animal and in-vitro studies showing relevant mechanisms - Limited clinical data for thymosin alpha-1 in acute COVID - Case reports and anecdotal accounts from physicians using peptides off-label - Theoretical frameworks based on known peptide mechanisms and proposed long COVID pathways

What we're missing: - Randomised controlled trials of any peptide for long COVID - Long-term safety data in post-COVID patients - Understanding of how post-viral immune dysregulation affects peptide response - Head-to-head comparisons of peptide approaches vs established treatments

Why this matters: Long COVID patients are understandably desperate for solutions. This vulnerability makes them targets for unproven treatments. While peptide research is scientifically interesting, no one should delay or replace evidence-based NHS care with unproven peptide protocols.

The NHS has established a network of Long COVID assessment services across England, Scotland, Wales, and Northern Ireland:

How to access: 1. Contact your GP with persistent symptoms (>12 weeks post-infection) 2. GP will conduct initial assessment and blood tests 3. Referral to a specialist Long COVID clinic if needed 4. Multidisciplinary team assessment (typically includes respiratory, cardiology, psychology, physiotherapy)

Available NHS treatments (evidence-based): - Pacing and energy management — the primary fatigue management strategy - Graded exercise therapy (carefully structured — NOT the controversial GET from ME/CFS) - Respiratory physiotherapy — breathing pattern retraining - Cognitive rehabilitation — for brain fog and concentration difficulties - Psychological support — CBT, counselling for adjustment and mood - Medication management — symptom-specific treatments (beta-blockers for tachycardia, etc.)

NICE guideline NG188 covers the assessment and management of long COVID symptoms.

Your COVID Recovery (NHS online rehabilitation programme) provides self-management resources.

These services should be the foundation of any long COVID management plan. Peptides, if considered at all, should complement — not replace — NHS care.

If you have long COVID and are considering peptides:

1. Engage with NHS services first. Access your local Long COVID clinic. The multidisciplinary approach addresses multiple symptom domains simultaneously.

2. Don't self-diagnose or self-treat. Long COVID symptoms overlap with many other conditions (thyroid disorders, anaemia, cardiac conditions). Proper diagnosis is essential.

3. Be cautious with immune-modulating peptides. Long COVID involves immune dysregulation — stimulating the immune system without understanding the specific dysregulation pattern could theoretically worsen symptoms.

4. Prioritise evidence-based fundamentals: - Pacing (the single most important fatigue management tool) - Adequate sleep and rest - Anti-inflammatory nutrition (Mediterranean diet pattern) - Gentle, graded activity (not pushing through fatigue) - Stress reduction

5. If you do explore peptides, do so only under qualified medical supervision with: - Baseline blood work (inflammatory markers, immune panels) - Regular monitoring - Clear documentation of symptoms before and after - Willingness to stop if no improvement or if symptoms worsen

6. Join a support group. Long COVID Support (longcovid.org) and Body Politic provide peer support and up-to-date research information.

*This guide is for educational purposes only. Long COVID is a complex medical condition requiring professional management. No peptide is approved for long COVID treatment. Consult your GP or Long COVID clinic for personalised care.*